Industries > Pharma > Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027

Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027

Outlook & Analysis for Ophthalmic Drugs for Other Retinal Diseases Including Age-Related Macular Degeneration (ARMD), Dry AMD, Wet AMD, Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) & Geographic Atrophy (GA)

PUBLISHED: 17 July 2017
PAGES: 196
PRODUCT CODE: PHA0213

Clear
WOOCS 2.2.1
SKU: PHA0213 Categories: , ,

Macular Degeneration, Diabetic Retinopathy and Other Retinal Diseases – our new study reveals trends, R&D progress, and predicted revenues
Where is the Retinal disease therapeutic market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 169-page report provides 80 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Retinal Disease market. See how to exploit the opportunities.

Forecasts from 2017-2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts to 2027 for the following submarkets:
• Wet age-related macular degeneration (wAMD)
• Dry AMD (dAMD)
• Diabetic retinopathy (DR)
• Other retinal diseases (grouped forecast).

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products’ sales – what’s possible for those eye drug revenues?
How will individual retinal medicines perform from 2017 to 2027 at world level? Our study forecasts revenues of four prominent brands:
• Lucentis
• Eylea
• Avastin
• Visudyne

Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027

Discover how high revenues can go. See what’s happening, understanding the trends, challenges and opportunities.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for 10 leading national markets from 2017-2027:
• United States (US)
• Japan
• Germany, France, the UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).

Leading companies and the potential for market growth
Our analysis forecasts that the world market for retinal drugs will reach $11.98bn in 2017. It will achieve strong revenue expansion from 2017 to 2027. Our report reveals how high sales will go over the next 10 years.

Research and development – assess innovation, trends and possibilities
There you can also investigate R&D, appraising technological, clinical and commercial possibilities.
In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others:
• Combination therapies, including neovascularisation disrupters
• Angiogenesis inhibition by blocking pericyte recruitment
• Anti-inflammatory mechanisms (inc. corticosteroids)
• Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
• Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore the other agents and possibilities, too, including these:
• Oligonucleotides and siRNA therapy
• Anti-integrin oligopeptide treatment
• Complement factor inhibition and serotonin modifiers
• Angiotensin receptor blockers and converting enzyme inhibitors
• Biosimilars and other follow-on biologicals and next generation therapeutics
• Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Get our report today Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027: Outlook & Analysis for Ophthalmic Drugs for Other Retinal Diseases Including Age-Related Macular Degeneration (ARMD), Dry AMD, Wet AMD, Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) & Geographic Atrophy (GA). Avoid missing out – get our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Macular Degeneration (AMD) & Diabetic Retinopathy (DR) Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories